8-K: Oncotelic Therapeutics Secures $178,410 via Convertible Note

Oncotelic Therapeutics, Inc. has entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note and commitment shares to raise $178,410.

Summary

• On June 23, 2026, Oncotelic Therapeutics, Inc. (the Company) entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP.
• The Company issued a convertible promissory note totaling $178,410.
• This note carries a 12% annual interest rate and a 12% original issue discount.
• The note matures one year from the agreement date or upon acceleration due to an Event of Default.
• Pacific Pier Capital II, LP can convert the note into shares of the Company's common stock at a fixed price of $0.06 per share or 85% of the lowest traded price during the ten trading days prior to conversion.
• The Company also issued 500,000 shares of common stock as commitment shares to Pacific Pier Capital II, LP.
• The issuance of the note and shares is exempt from registration under the Securities Act of 1933, relying on Section 4(a)(2).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While it secures necessary capital, the terms of the convertible note, including the discount, interest, and potential for significant dilution, present financial burdens and risks for existing shareholders.

Positives

• Secured $178,410 in funding through a convertible note.
• Received 500,000 commitment shares, indicating investor commitment.
• The conversion price is fixed at $0.06 or a discount to market, potentially offering upside for the investor.
• The transaction is structured to be exempt from registration requirements, simplifying the process.

Negatives

• The convertible note has a significant original issue discount of 12%, diluting the effective capital raised.
• The note carries a 12% annual interest rate, adding to the cost of capital.
• The conversion price can be as low as 85% of the lowest traded price, potentially leading to significant dilution if the stock price is low.
• Events of Default can trigger immediate repayment with a default interest rate of 16%, increasing financial risk.
• The issuance of 500,000 commitment shares represents immediate dilution to existing shareholders.

Risks

• Potential for significant dilution of common stock upon conversion of the note, especially if the stock price declines.
• The company faces the risk of default, which would trigger accelerated repayment with higher interest.
• The fixed conversion price of $0.06 per share could be significantly higher than future market prices, leading to substantial dilution.
• The company's ability to repay the note or manage its conversion will depend on its future financial performance and market conditions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the terms of the financing agreement. The company's future outlook will be influenced by its ability to manage the convertible note and its operational progress.

Management Comments

• The filing is a factual disclosure of a material definitive agreement and does not include direct management commentary.
• The signature by Vuong Trieu, Chief Executive Officer, indicates executive approval of the reported transaction.

Industry Context

StockSavvy.ai notes that this type of financing, involving convertible notes with discounts and warrants (implied by commitment shares), is common for early-stage or development-stage biotechnology companies seeking capital to fund ongoing research and clinical trials. Such instruments often carry higher interest rates and dilution risks compared to traditional debt or equity offerings.

Stakeholder Impact

• Shareholders: Potential for significant dilution of ownership percentage and earnings per share due to the conversion of the note and issuance of commitment shares.
• Creditors: The company's increased debt obligation (via the convertible note) could impact its creditworthiness.
• Management: The CEO has approved a financing agreement that carries dilutionary aspects, requiring careful management of future stock performance.

Next Steps

• Oncotelic Therapeutics will need to manage the convertible note, including interest payments and potential conversion.
• The company will continue its operations, presumably funded in part by this capital raise.
• Pacific Pier Capital II, LP may convert the note into common stock based on market conditions and the conversion terms.

Key Dates

Recommendation

The filing indicates a necessary capital raise but with terms that suggest potential future dilution and financial pressure. While the company is securing funds to continue operations, the specifics of the convertible note warrant a cautious 'hold' stance until further clarity on operational progress and the impact of potential dilution emerges.

Keywords

Oncotelic Therapeutics, 8-K Filing, Convertible Note, Securities Purchase Agreement, Pacific Pier Capital, Equity Financing, Dilution, Common Stock, Biotechnology